Form 4: Verona Pharma Director Awarded 96,000 Restricted Share Units

Director David R. Ebsworth receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.

Summary

• David R. Ebsworth, a director of Verona Pharma plc, was granted 96,000 Restricted Share Units (RSUs) on April 25, 2025.
• Each RSU represents the right to receive one American Depositary Share (ADS), and each ADS represents eight ordinary shares of Verona Pharma.
• The RSUs will vest in four equal installments of 25% each, on August 1, 2025, November 1, 2025, February 1, 2026, and May 1, 2026.
• Vesting is contingent upon Ebsworth's continued service to Verona Pharma on each vesting date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the company's future performance. It also aligns the director's interests with those of the shareholders.

Positives

• The granting of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the RSUs is dependent on the future performance of Verona Pharma's stock price, which is subject to market risks.
• If the director leaves the company before the RSUs fully vest, they will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Equity compensation, such as RSUs, is a common practice in the pharmaceutical industry to attract and retain key personnel and align their interests with those of the shareholders.

Comparison to Industry Standards

• RSUs are a standard form of equity compensation used across the pharmaceutical industry.
• Companies like AstraZeneca, GlaxoSmithKline, and Novartis also utilize RSUs as part of their executive compensation packages.
• The vesting schedule of the RSUs is typical, with quarterly or annual vesting periods being common.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see the RSU grant as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Restricted Share Units, RSUs, Verona Pharma, Director, David R. Ebsworth, Equity Compensation, Form 4, ADS, Ordinary Shares, Vesting